Research Center

Ortho Illinois has long held a commitment to continuing medical education and providing university-level care.  In 2006, it was a natural next step to formalize a program that allows our physicians to participate in the process that contributes to medical research and makes revolutionary new products and treatments possible.

Be a part of our clinical studies:

Printable Research Participant Flyer 1

Printable Research Flyer 2

Yes! I want to know more about being a research study patient! (Online submission)

Studies Currently Active and Enrolling

1. A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumad to Placebo in Subjects with Active Psoriatic Arthritis )PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug – Dr. Saad Tariq, Riverside Office.
2. A Prospective, Multicenter Post-Market Clinical Follow-up Study to Evaluate the Safety and Performance of the Knee System – Dr. Mark Oyer, Riverside Office.
3. A Randomized, Controlled Pragmatic Phase 3b/4 Study of Patients with Rheumatoid Arthritis – Dr. Andrew Jasek, Riverside Office.
4. A Randomized, Controlled Pragmatic Phase 3b/4 Study of Patients with Rheumatoid Arthritis – Dr. Husna Siddiqui & Dr. Matas Orentas, Elgin Office.
5. A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Bio-Naive Participants with Active Psoriatic Arthritis Axial Disease – Dr. Saad Tariq & Dr. Albert Liang, Riverside Office.
6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, for Patients with Moderately to Severely Active Systemic Lupus Erythematosus – Dr. Albert Liang, Riverside Office.
7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Part 2 Study in Patients with Moderately to Severely Active Systemic Lupus Erythematosus – Dr. Albert Liang, Riverside Office.
8. A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, in Subjects with moderate to Severe Theumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor -Dr. Saad Tariq, Riverside Office.
9. A Phase 3 Program to Evaluate the Safety of study drugs in Subjects with Moderately to Severely Active SLE – Dr. Saad Tariq, Riverside Office.
10. A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Participants With Sjogren’s Syndrome With Moderate to Severe Systemic Disease Activity – Dr. Saad Tariq, Dr. Andrew Jasek & Dr. Albert Liang, Riverside Office.
11. A Phase 3 Randomized, Double-blind, Placebo-controlled Study Part 2 in Participants With Sjogren’s Syndrome With Moderate-to-Severe Systemic Disease Activitiy – Dr. Saad Tariq, Dr. Andrew Jasek & Dr. Albert Liang, Riverside Office.
12. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to in Participants with Sjogren’s Disease – Dr. Saad Tariq, Riverside Office.
13. A Phase 4, Multicenter, Prospective, Open-label Study in Adult Participants with Early Systemic Lupus Erythematosus – Dr. Husna Siddiqui & Dr. Matas Orentas, Elgin Office.
14. Prospective, Multi-center, Post-Market Clinical Follow-up Study to Evaluate Safety and Performance of the Suture Anchor in Shoulder Rotator Cuff Tendon Repair – Dr. Scott Trenhaile, Roxbury Office.
15. An Open-Label, Multicenter, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiolographic Outcome – Dr. Scott Trenhaile, Roxbury Office.
16. An Open-Label, Multicenter, Retrospective and Prospective Evaluation of Shoulder Arthroplasty Clinical and Radiographic Outcome – Dr. Rolando Izquierdo, Elgin Office.
17. An Open-Label, Multicenter, Retrospective and prospective Evaluation of Shoulder Arthroplasty Clinical and Rediographic Outcome – Dr. Rolando Izquierdo, Algonquin Office.
18. Evaluation of safety and efficacy of a resorbable collagen implant in treatment of High-Grade Partial Thickness Tears; A prospective, multicenter, randomized, control trial – Dr. Scott Trenhaile, Roxbury Office.
19. Autologous chondrocyte implantation Post Registry Protocol – Dr. Geoffrey Van Thiel, Roxbury Office.
20. A Multicenter, Prospective Clinical Study Analyzing Outcomes of Shoulder Arthroplasty – Dr. Rolando Izquierdo, Algonquin Office.

About Clinical Research:

Clinical research studies are biomedical or health-related studies that involve patients with a targeted diagnosis. Depending on the specific study, there are usually 50-100 sites nationally or internationally participating in a particular study. Sites are carefully selected based on state-of-the-art diagnostic and facility criteria and by the commitment demonstrated by the physicians involved in top quality patient care.

By participating in national and international clinical research studies at the Phase II-IV levels, Ortho Illinois physicians have access to new treatment options for patients on a local level who have not experienced improvement through other treatments.

Currently, Ortho Illinois has executed over 100 clinical research and post market studies. We are proud to participate in the first-in-class drug studies for the treatment of rheumatoid arthritis, notably Xejanz®, Tremfya®, and Otezla® and finding treatments for medical conditions such as systemic lupus erythematosus, Sjogren’s syndrome, psoriatic arthritis and polymyositis.  We seek advanced medical device studies including biodegradable materials or using the body’s own stem cells to heal joint damage.   By gaining years’ of experience using cutting edge technologies, our physicians already have the expertise you desire once a new drug or device is approved by the FDA.

In addition to expanding physicians’ experience and knowledge, being in a clinical trial offers great benefits to patients.  Study participants gain access to new research treatments before FDA approval or availability, receive more services, are assessed more frequently, and have a more active role in their health care.  Participating in a research study offers travel reimbursements as well as health safety monitoring.  Our clinical trial site assists patients with high co-pays or who do not have healthcare coverage.  All laboratory, medication, and physician costs specific to the study are covered for the patient participant by the company conducting the study.

For further information about research studies contact:

Catherine M. Ayala, PharmD, Director of Clinical Research  at 815-381-7482, catherine.ayala@orthoillinois.com.

Rubinder Kaur, MS, Clinical Research Coordinator, at 815-381-7457, rubinder.kaur@orthoillinois.com